Hazelwood based Mallinckrodt Pharmaceuticals has shaken hands on a deal with Amneal Pharmaceuticals to distribute medications to addiction treatment centers.
The Covidien spinoff, which claimed its independence this summer, will ensure Buprenorphine HCl and Naloxone HCl Dihydrate two a generic version of Suboxone, a medication used to help with opioid dependence, makes it to clinics for the next three years.
There is an option to extend written into the agreement. Mallinckrodt is a major supplier of generic opioid dependence products to U.S. addiction treatment centers, according to a company statement.
The contract amount of the dealt was not released.